Muhammet şenkal

Dr. Muhammet şenkal

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
HBHamza Ugur Bozbey
Hamza Ugur Bozbey
DTDidem Taştekin
Didem Taştekin
Objective: This study primarily aimed to identify baseline clinical and laboratory predictors of hematologic toxicity during first-line platinum-based chemotherapy in BRCA-mutated ovarian cancer patients. Secondary objectives included describing toxicity patterns and evaluating the association between hematologic toxicity and survival outcomes. Methods: This retrospective study included 64 patients with BRCA-mutated ovarian cancer who received platinum-taxane-based chemotherapy and were followed up at the İstanbul University Institute of Oncology between January 2009 and September 2024. Hematological toxicity was assessed using complete blood count before each chemotherapy cycle. Clinical data, factors associated with toxicity, and survival outcomes were compared between groups. Results: Hematologic toxicity occurred in 29.7% of the patients. The baseline leukocyte, neutrophil, and platelet counts were significantly lower in patients with toxicity. Additionally, patients with toxicities had more comorbidities at the baseline. Although the rate of dose modification was higher in the hematologic toxicity group, there were no significant differences between the groups in terms of treatment response or survival outcomes. Conclusion: Although hematologic toxicity was associated with more frequent dose modifications, no statistically significant differences in survival outcomes were observed between the groups. Baseline hematologic values and comorbidities should be considered in individualized planning of chemotherapy. Large-scale prospective studies are warranted to enhance the understanding of this topic. Cite this article as: Çokgezer S, Senkal M, Safaraliyeva A, Bozbey HU, Taştekin D. Hematologic toxicity during first-line platinum-based chemotherapy in BRCA-mutated ovarian cancer: predictors and survival impact. Cerrahpaşa Med J 2026; 50, 0033, doi: 10.5152/cjm.2026.26033.

16 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
NANaziye Ak
Naziye Ak
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
DTDidem Tastekin
Didem Tastekin
PSPınar Mualla Saip
Pınar Mualla Saip
Background and Objectives: This study aimed to comparatively evaluate the association of commonly used comorbidity scores with survival, mortality, and recurrence in ovarian cancer patients aged 50 years and above. Materials and Methods: In this single-center, retrospective study, 130 female patients diagnosed between 2017 and 2024 who had received systemic therapy and had complete medical records were included. Comorbidity scores—including the Charlson Comorbidity Index (CCI), Cumulative Illness Rating Scale-Geriatric (CIRS-G), Adult Comorbidity Evaluation-27 (ACE-27), Elixhauser Comorbidity Index, Index of Coexistent Disease (ICED), and Functional Comorbidity Index (FCI)—were calculated for each patient. Survival analyses were conducted using the Kaplan–Meier method and Cox regression modeling. The prognostic accuracy of comorbidity scores was assessed via receiver operating characteristic (ROC) curve analysis. Results: Patients with higher CCI scores had significantly shorter survival, and CCI was identified as an independent prognostic factor in multivariate analysis. While other comorbidity scores were associated with overall survival in univariate analyses, they lost statistical significance in multivariate models. Patients with a higher comorbidity burden experienced more frequent disease recurrence and shorter time to recurrence. Conclusions: Comorbidity burden is a key clinical determinant of survival and disease trajectory in older patients with ovarian cancer. The CCI demonstrated the highest prognostic accuracy in this population and may serve as a valuable tool in individualized treatment planning. Integration of comorbidity-based assessments into standard decision-making processes is recommended in geriatric oncology practice.

26 May 2021 in Research Square
Verified
Preprint
Open access
PDF file
MŞMuhammet şenkal
Muhammet şenkal
IAIbrahim Akalin
Ibrahim Akalin
We aimed to compare the human genome with the olive genome on the hypothetical context of whether or not any human-plant genomic alignment similarities could give rise to genomic bioavailability when consumed likewise carbohydrates, proteins, fats. Many studies from past to present have shown beneficial effects of olives on cardiovascular diseases and some cancer pathways. Moreover, scientific and even religious resources highlighted the importance of the olive. In our project, we aligned the olive genome with the human genome in Pubmed Blast database. We detected several genes has had 100 percent matching sequences where pathological and non-pathological variations were identified in the human genome. Interestingly wild type variations were observed in the olive genome and those matching regions were consuming restriction sites. In our data, matching regions at cardiovascular and cancer-related genes could suggest a possible bioavailability of plant genomes even in vitro. Further studies, comparing other plant genomes with the human genome would beget more promising results.

14 August 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
SASelay Artan
Selay Artan
STSevde Topuz
Sevde Topuz
MŞMuhammet şenkal
Muhammet şenkal
AAAbdulmunir Azizy
Abdulmunir Azizy
SKSenem Karabulut
Senem Karabulut
Objective: This study aimed to evaluate the impact of anti-epidermal growth factor receptor (anti-EGFR)–based maintenance therapy administered after first-line chemotherapy combined with anti-EGFR treatment on progression-free survival (PFS) and overall survival (OS) in patients with RAS wild-type metastatic colorectal cancer (mCRC), using real-world data. Methods: Patients followed at a single center between 2015 and 2025 were retrospectively analyzed. A total of 37 RAS wild-type patients who achieved disease control after first-line chemotherapy combined with anti-EGFR therapy were included. Patients were divided into a maintenance therapy group (n = 19) and an active surveillance group (n = 18). Survival analyses were performed using the Kaplan–Meier method, groups were compared using the log-rank test, and a landmark approach was applied to minimize immortal time bias. Results: At a median follow-up of 27.4 months, median PFS was 11.4 months in the maintenance group and 5.4 months in the surveillance group, without reaching statistical significance (P = .133). In contrast, median OS was significantly longer in the maintenance group (56.9 months vs. 9.6 months; P = .041). Additionally, higher rates of transition to subsequent lines of therapy were observed in patients receiving maintenance therapy. Conclusion: Anti-EGFR–based maintenance therapy was associated with numerically prolonged PFS and improved treatment continuity in patients with RAS wild-type mCRC. Although a significant difference in OS was observed, this finding should be interpreted cautiously given the limited sample size, retrospective design, and potential influence of selection bias and subsequent therapies. Larger prospective studies are warranted to better define the role of anti-EGFR maintenance therapy in clinical practice. Cite this article as: Çokgezer S, Artan S, Topuz S, et al. Effect of maintenance anti-EGFR therapy on survival in RAS wild-type metastatic colorectal cancer: real-world data. Cerrahpaşa Med J 2026, 50, 0069, doi: 10.5152/cjm.2026.26069.

25 November 2025 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
SÇSimay Çokgezer
Simay Çokgezer
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
HKHelin Kose
Helin Kose
IYInci Kizildag Yirgin
Inci Kizildag Yirgin
NANaziye Ak
Naziye Ak

28 March 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
ASAysel Seferaliyeva
Aysel Seferaliyeva
STSevde Topuz
Sevde Topuz
MŞMuhammet şenkal
Muhammet şenkal
NANaziye Ak
Naziye Ak
PSPınar Mualla Saip
Pınar Mualla Saip
Background and Objectives: Invasive lobular carcinoma (ILC) is a breast cancer subtype with a controversial surgical management due to its diffuse infiltrative growth pattern and increased tendency for multicentricity. This study aimed to compare the effects of breast-conserving surgery (BCS) and mastectomy on long-term overall survival (OS) and progression-free survival (PFS) in patients diagnosed with ILC. Materials and Methods: In this single-center, retrospective, observational study, 255 patients with histopathologically confirmed ILC between 2017 and 2025 were included. Patients who underwent surgical treatment were divided into two groups according to the surgical approach: BCS (n = 94) and mastectomy (n = 141). Survival analyses were performed using the Kaplan–Meier method, and comparisons between groups were assessed with the log-rank test. Factors affecting survival were evaluated using Cox regression analysis. Results: The median age of the patients was 53 years (range, 28–85), and the median follow-up duration was 31.8 months. Of the cases, 76.9% were classic-type ILC and 70.9% had stage I–II disease. The rate of negative surgical margins was 87.6%. No statistically significant differences were observed between the BCS and mastectomy groups in terms of estimated median PFS (87.4 months vs. 86.7 months; p > 0.05) or estimated median OS (87.7 months vs. 115.7 months; p > 0.05). Multivariable analyses demonstrated that the type of surgery was not an independent prognostic factor for survival. Conclusions: This study shows that, with appropriate patient selection and adequate surgical margin control, BCS provides oncologic survival outcomes comparable to mastectomy in ILC. The choice of surgical approach should be individualized based on tumor biology, stage, and multidisciplinary evaluation rather than histological subtype alone.